Akèy › Kansè poumon › Pennsylvania › York
Etid klinik pou Kansè poumon nan York, PA
8 etid pou Kansè poumon ap chèche patisipan nan sit nan ak bò kote York (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- WellSpan Health-York Cancer Center, York
- WellSpan Health-York Hospital, York
- UPMC Memorial, York
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- WellSpan York Cancer Center, York
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Ap rekriteFaz 3
- WellSpan Health-York Cancer Center, York
- WellSpan Health-York Hospital, York
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- WellSpan Health-York Cancer Center, York
- WellSpan Health-York Hospital, York
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- WellSpan Health-York Cancer Center, York
- UPMC Memorial, York
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Cancer Care Associates of York, York
- WellSpan Health-York Cancer Center, York
- WellSpan Health-York Hospital, York
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- Cancer Care Associates of York, York
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Ap rekriteFaz 1/2
- Cancer Care Associates of York (site 206), York
Etid Kansè poumon nan lòt vil
- Houston, TX78 etid
- Boston, MA62 etid
- New York City, NY60 etid
- Los Angeles, CA45 etid
- Washington, DC41 etid
- Arlington, VA41 etid
- Chicago, IL41 etid
- Nashville, TN40 etid
- Baltimore, MD40 etid
- St. Louis, MO39 etid
- Columbus, OH37 etid
- Philadelphia, PA36 etid
Lòt etid nan York
- Kansè Poumon ki pa ti selil15 etid
- Kansè (tout kalite)8 etid
- Kansè nan tete8 etid
- Karsinòm selil skuamèz tèt ak kou7 etid
- Kansè ovè6 etid
- Kansè pwostat5 etid
- Maladi atè koronè5 etid
- Kansè kolorektal4 etid
- Kansè Endomèt4 etid
- Kansè tete negatif triple4 etid
- Kansè Ezofajyen4 etid
- Melanom3 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.